Tofacitinib in Acute Severe Ulcerative Colitis (TACOS): A Randomized Controlled Trial

医学 托法替尼 溃疡性结肠炎 安慰剂 优势比 内科学 置信区间 随机化 随机对照试验 人口 英夫利昔单抗 外科 类风湿性关节炎 疾病 替代医学 环境卫生 病理
作者
Arshdeep Singh,Manjeet Kumar Goyal,Vandana Midha,Ramit Mahajan,Kirandeep Kaur,Yogesh Gupta,Dharmatma Singh,Namita Bansal,Ramandeep Kaur,Shivam Kalra,Omesh Goyal,Varun Mehta,Ajit Sood
出处
期刊:The American Journal of Gastroenterology [Lippincott Williams & Wilkins]
卷期号:119 (7): 1365-1372 被引量:44
标识
DOI:10.14309/ajg.0000000000002635
摘要

INTRODUCTION: Intravenous corticosteroids are the mainstay of treatment of patients hospitalized with acute severe ulcerative colitis (ASUC). However, 30%–40% of the patients are refractory to corticosteroids. We investigated whether addition of tofacitinib to corticosteroids improved the treatment responsiveness in patients with ASUC. METHODS: This single-center, double-blind, placebo-controlled trial randomized adult patients with ASUC (defined by the Truelove Witts severity criteria) to receive either tofacitinib (10 mg thrice daily) or a matching placebo for 7 days while continuing intravenous corticosteroids (hydrocortisone 100 mg every 6 hours). The primary end point was response to treatment (decline in the Lichtiger index by >3 points and an absolute score <10 for 2 consecutive days without the need for rescue therapy) by day 7. The key secondary outcome was the cumulative probability of requiring initiation of infliximab or undergoing colectomy within 90 days following randomization. All analyses were performed in the intention-to-treat population. RESULTS: A total of 104 patients were randomly assigned to a treatment group (53 to tofacitinib and 51 to placebo). At day 7, response to treatment was achieved in 44/53 (83.01%) patients receiving tofacitinib vs 30/51 (58.82%) patients receiving placebo (odds ratio 3.42, 95% confidence interval 1.37–8.48, P = 0.007). The need for rescue therapy by day 7 was lower in the tofacitinib arm (odds ratio 0.27, 95% confidence interval 0.09–0.78, P = 0.01). The cumulative probability of need for rescue therapy at day 90 was 0.13 in patients who received tofacitinib vs 0.38 in patients receiving placebo (log-rank P = 0.003). Most of the treatment-related adverse effects were mild. One patient, receiving tofacitinib, developed dural venous sinus thrombosis. DISCUSSION: In patients with ASUC, combination of tofacitinib and corticosteroids improved treatment responsiveness and decreased the need for rescue therapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
2秒前
3秒前
3秒前
思源应助qx采纳,获得10
3秒前
跳跃傲安完成签到,获得积分20
4秒前
4秒前
孙sy发布了新的文献求助10
5秒前
油炸关注了科研通微信公众号
5秒前
阿狄丽娜发布了新的文献求助10
5秒前
6秒前
李汝嘉发布了新的文献求助10
7秒前
7秒前
Qing发布了新的文献求助30
8秒前
8秒前
9秒前
10秒前
乐乐应助沉溺采纳,获得10
10秒前
11秒前
TuTu发布了新的文献求助10
11秒前
ni完成签到,获得积分20
11秒前
12秒前
yookia应助舒服的冰绿采纳,获得10
13秒前
13秒前
赤练仙子发布了新的文献求助10
13秒前
不加糖发布了新的文献求助30
13秒前
温柔诗柳完成签到,获得积分10
16秒前
16秒前
dild发布了新的文献求助10
17秒前
17秒前
17秒前
钢铁科研完成签到,获得积分10
17秒前
hh发布了新的文献求助10
20秒前
momomi完成签到,获得积分10
20秒前
Gideon发布了新的文献求助10
20秒前
21秒前
21秒前
22秒前
23秒前
高分求助中
The Mother of All Tableaux Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 2400
Ophthalmic Equipment Market by Devices(surgical: vitreorentinal,IOLs,OVDs,contact lens,RGP lens,backflush,diagnostic&monitoring:OCT,actorefractor,keratometer,tonometer,ophthalmoscpe,OVD), End User,Buying Criteria-Global Forecast to2029 2000
Optimal Transport: A Comprehensive Introduction to Modeling, Analysis, Simulation, Applications 800
Official Methods of Analysis of AOAC INTERNATIONAL 600
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 588
T/CIET 1202-2025 可吸收再生氧化纤维素止血材料 500
Comparison of adverse drug reactions of heparin and its derivates in the European Economic Area based on data from EudraVigilance between 2017 and 2021 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3952902
求助须知:如何正确求助?哪些是违规求助? 3498332
关于积分的说明 11091532
捐赠科研通 3228969
什么是DOI,文献DOI怎么找? 1785163
邀请新用户注册赠送积分活动 869202
科研通“疑难数据库(出版商)”最低求助积分说明 801377